Outcomes of cardiac resynchronization therapy (CRT) in cardiac sarcoidosis patients with a range of ejection fractions

Abstract Aims In cardiac sarcoidosis (CS) patients, the benefit of cardiac resynchronization therapy (CRT) remains unclear. We sought to assess the short‐term and long‐term effects of CRT in CS patients with a range of left ventricular (LV) ejection fractions (LVEFs). Methods Consecutive CS patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Alexander Liu, Raheel Ahmed, Mansimran Singh Dulay, Joseph Okafor, Alessia Azzu, Kamleshun Ramphul, Rui Shi, Gerald Ballo, John Arun Baksi, Kshama Wechalekar, Rajdeep Khattar, Peter Collins, Athol Umfrey Wells, Vasilis Kouranos, Rakesh Sharma
Format: Article
Language:English
Published: Wiley 2025-02-01
Series:ESC Heart Failure
Subjects:
Online Access:https://doi.org/10.1002/ehf2.15113
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850186322376916992
author Alexander Liu
Raheel Ahmed
Mansimran Singh Dulay
Joseph Okafor
Alessia Azzu
Kamleshun Ramphul
Rui Shi
Gerald Ballo
John Arun Baksi
Kshama Wechalekar
Rajdeep Khattar
Peter Collins
Athol Umfrey Wells
Vasilis Kouranos
Rakesh Sharma
author_facet Alexander Liu
Raheel Ahmed
Mansimran Singh Dulay
Joseph Okafor
Alessia Azzu
Kamleshun Ramphul
Rui Shi
Gerald Ballo
John Arun Baksi
Kshama Wechalekar
Rajdeep Khattar
Peter Collins
Athol Umfrey Wells
Vasilis Kouranos
Rakesh Sharma
author_sort Alexander Liu
collection DOAJ
description Abstract Aims In cardiac sarcoidosis (CS) patients, the benefit of cardiac resynchronization therapy (CRT) remains unclear. We sought to assess the short‐term and long‐term effects of CRT in CS patients with a range of left ventricular (LV) ejection fractions (LVEFs). Methods Consecutive CS patients with heart failure with reduced ejection fraction (HFrEF; LVEF ≤ 40%), mildly reduced ejection fraction (HFmrEF; LVEF 41%–49%) and preserved ejection fraction (HFpEF; LVEF ≥ 50) treated with CRT under the care of a tertiary UK centre between 2008 and 2023 were reviewed. CRT response was defined by >5% improvement in serial LVEF. The primary endpoint was a composite of all‐cause mortality, cardiac transplantation or unplanned hospitalization for decompensated heart failure. The secondary endpoint included ventricular arrhythmic events. Results Of the 100 patients enrolled (age 58 ± 10 years; 71% male), 63 had HFrEF, 17 had HFmrEF and 20 had HFpEF. After short‐term follow‐up (9.8 ± 5.4 months), HFrEF patients demonstrated significant LVEF response (P < 0.01). On Kaplan–Meier analysis (follow‐up 38 ± 32 months), HFrEF non‐responders had significantly worse event‐free survival compared with HFrEF responders for the primary (P < 0.001) and secondary (P = 0.001) endpoints. Despite short‐term LV function improvement, CRT responders still had worse event‐free survival compared with HFmrEF/HFpEF patients for the primary endpoint (P < 0.001). On multivariable Cox analysis, age [hazard ratio (HR) 1.05, 95% confidence interval (CI) 1.01–1.10, P = 0.008] and HFrEF CRT non‐response (HR 12.33, 95% CI 2.45–61.87, P = 0.002) were associated with the primary endpoint. Conclusions In CS patients with HFrEF, CRT response is associated with a better long‐term prognosis than non‐response. However, HFrEF CRT responders still have worse long‐term prognosis than HFmrEF/HFpEF patients.
format Article
id doaj-art-81f2ec5bdf704e70bb782001b70d861c
institution OA Journals
issn 2055-5822
language English
publishDate 2025-02-01
publisher Wiley
record_format Article
series ESC Heart Failure
spelling doaj-art-81f2ec5bdf704e70bb782001b70d861c2025-08-20T02:16:22ZengWileyESC Heart Failure2055-58222025-02-0112159260210.1002/ehf2.15113Outcomes of cardiac resynchronization therapy (CRT) in cardiac sarcoidosis patients with a range of ejection fractionsAlexander Liu0Raheel Ahmed1Mansimran Singh Dulay2Joseph Okafor3Alessia Azzu4Kamleshun Ramphul5Rui Shi6Gerald Ballo7John Arun Baksi8Kshama Wechalekar9Rajdeep Khattar10Peter Collins11Athol Umfrey Wells12Vasilis Kouranos13Rakesh Sharma14Royal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust London UKRoyal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust London UKRoyal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust London UKRoyal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust London UKRoyal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust London UKIndependent Researcher Triolet MauritiusRoyal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust London UKRoyal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust London UKRoyal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust London UKRoyal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust London UKRoyal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust London UKRoyal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust London UKRoyal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust London UKRoyal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust London UKRoyal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust London UKAbstract Aims In cardiac sarcoidosis (CS) patients, the benefit of cardiac resynchronization therapy (CRT) remains unclear. We sought to assess the short‐term and long‐term effects of CRT in CS patients with a range of left ventricular (LV) ejection fractions (LVEFs). Methods Consecutive CS patients with heart failure with reduced ejection fraction (HFrEF; LVEF ≤ 40%), mildly reduced ejection fraction (HFmrEF; LVEF 41%–49%) and preserved ejection fraction (HFpEF; LVEF ≥ 50) treated with CRT under the care of a tertiary UK centre between 2008 and 2023 were reviewed. CRT response was defined by >5% improvement in serial LVEF. The primary endpoint was a composite of all‐cause mortality, cardiac transplantation or unplanned hospitalization for decompensated heart failure. The secondary endpoint included ventricular arrhythmic events. Results Of the 100 patients enrolled (age 58 ± 10 years; 71% male), 63 had HFrEF, 17 had HFmrEF and 20 had HFpEF. After short‐term follow‐up (9.8 ± 5.4 months), HFrEF patients demonstrated significant LVEF response (P < 0.01). On Kaplan–Meier analysis (follow‐up 38 ± 32 months), HFrEF non‐responders had significantly worse event‐free survival compared with HFrEF responders for the primary (P < 0.001) and secondary (P = 0.001) endpoints. Despite short‐term LV function improvement, CRT responders still had worse event‐free survival compared with HFmrEF/HFpEF patients for the primary endpoint (P < 0.001). On multivariable Cox analysis, age [hazard ratio (HR) 1.05, 95% confidence interval (CI) 1.01–1.10, P = 0.008] and HFrEF CRT non‐response (HR 12.33, 95% CI 2.45–61.87, P = 0.002) were associated with the primary endpoint. Conclusions In CS patients with HFrEF, CRT response is associated with a better long‐term prognosis than non‐response. However, HFrEF CRT responders still have worse long‐term prognosis than HFmrEF/HFpEF patients.https://doi.org/10.1002/ehf2.15113cardiac resynchronization therapycardiac sarcoidosisoutcomes
spellingShingle Alexander Liu
Raheel Ahmed
Mansimran Singh Dulay
Joseph Okafor
Alessia Azzu
Kamleshun Ramphul
Rui Shi
Gerald Ballo
John Arun Baksi
Kshama Wechalekar
Rajdeep Khattar
Peter Collins
Athol Umfrey Wells
Vasilis Kouranos
Rakesh Sharma
Outcomes of cardiac resynchronization therapy (CRT) in cardiac sarcoidosis patients with a range of ejection fractions
ESC Heart Failure
cardiac resynchronization therapy
cardiac sarcoidosis
outcomes
title Outcomes of cardiac resynchronization therapy (CRT) in cardiac sarcoidosis patients with a range of ejection fractions
title_full Outcomes of cardiac resynchronization therapy (CRT) in cardiac sarcoidosis patients with a range of ejection fractions
title_fullStr Outcomes of cardiac resynchronization therapy (CRT) in cardiac sarcoidosis patients with a range of ejection fractions
title_full_unstemmed Outcomes of cardiac resynchronization therapy (CRT) in cardiac sarcoidosis patients with a range of ejection fractions
title_short Outcomes of cardiac resynchronization therapy (CRT) in cardiac sarcoidosis patients with a range of ejection fractions
title_sort outcomes of cardiac resynchronization therapy crt in cardiac sarcoidosis patients with a range of ejection fractions
topic cardiac resynchronization therapy
cardiac sarcoidosis
outcomes
url https://doi.org/10.1002/ehf2.15113
work_keys_str_mv AT alexanderliu outcomesofcardiacresynchronizationtherapycrtincardiacsarcoidosispatientswitharangeofejectionfractions
AT raheelahmed outcomesofcardiacresynchronizationtherapycrtincardiacsarcoidosispatientswitharangeofejectionfractions
AT mansimransinghdulay outcomesofcardiacresynchronizationtherapycrtincardiacsarcoidosispatientswitharangeofejectionfractions
AT josephokafor outcomesofcardiacresynchronizationtherapycrtincardiacsarcoidosispatientswitharangeofejectionfractions
AT alessiaazzu outcomesofcardiacresynchronizationtherapycrtincardiacsarcoidosispatientswitharangeofejectionfractions
AT kamleshunramphul outcomesofcardiacresynchronizationtherapycrtincardiacsarcoidosispatientswitharangeofejectionfractions
AT ruishi outcomesofcardiacresynchronizationtherapycrtincardiacsarcoidosispatientswitharangeofejectionfractions
AT geraldballo outcomesofcardiacresynchronizationtherapycrtincardiacsarcoidosispatientswitharangeofejectionfractions
AT johnarunbaksi outcomesofcardiacresynchronizationtherapycrtincardiacsarcoidosispatientswitharangeofejectionfractions
AT kshamawechalekar outcomesofcardiacresynchronizationtherapycrtincardiacsarcoidosispatientswitharangeofejectionfractions
AT rajdeepkhattar outcomesofcardiacresynchronizationtherapycrtincardiacsarcoidosispatientswitharangeofejectionfractions
AT petercollins outcomesofcardiacresynchronizationtherapycrtincardiacsarcoidosispatientswitharangeofejectionfractions
AT atholumfreywells outcomesofcardiacresynchronizationtherapycrtincardiacsarcoidosispatientswitharangeofejectionfractions
AT vasiliskouranos outcomesofcardiacresynchronizationtherapycrtincardiacsarcoidosispatientswitharangeofejectionfractions
AT rakeshsharma outcomesofcardiacresynchronizationtherapycrtincardiacsarcoidosispatientswitharangeofejectionfractions